Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | BPTF | Q12830 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5773564 | 0.79 | CHRNA1 (0.35) | L3MBTL1MAPTKMT2AMAPK1MEN1 | |
| SCHEMBL5777244 | 0.75 | P2RX7 (0.36) | KMT2AMAPK1 | |
| SCHEMBL6152284 | 0.75 | PHGDH (0.31) | — | |
| SCHEMBL6152911 | 0.75 | ALDH1A1 (0.40) | TSHRL3MBTL1KMT2AMEN1 | |
| SCHEMBL5776425 | 0.75 | HSD11B1 (0.39) | POLBL3MBTL1MAPTNPSR1KMT2A | |
| SCHEMBL5777514 | 0.73 | KMT2A (0.38) | TSHRL3MBTL1TRPV1MAPTNPSR1 | |
| SCHEMBL5774115 | 0.73 | THRB (0.36) | POLBKMT2AMAPK1 | |
| SCHEMBL5776474 | 0.72 | CNR1 (0.34) | L3MBTL1MAPTNPSR1KMT2AMEN1 | |
| SCHEMBL5777311 | 0.72 | KMT2A (0.36) | L3MBTL1TRPV1MAPTKMT2A | |
| SCHEMBL5778953 | 0.71 | ALDH1A1 (0.41) | L3MBTL1KMT2AMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406888-B1 | SUBSTITUTED Y-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2006-05-24 | — | — | EP | claimed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | claimed |
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406888-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004483-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| EP-1406888-B1 | SUBSTITUTED Y-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | GRUENENTHAL GMBH (DE) | 2006-05-24 | — | — | EP | disclosed |
| US-6956055-B2 | Substituted γ-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2005-10-18 | — | — | US | disclosed |
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406888-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004483-A1 | SUBSTITUTED $G(G)-LACTONE COMPOUNDS SERVING AS NMDA ANTAGONISTS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171677-A1 | Substituted gamma-lactone compounds as NMDA-antagonists | GRIN1, GRIN3A, GRIK5 | TSHR 4135/4885POLB 4263/4885L3MBTL1 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.